CGC Quote, Financials, Valuation and Earnings

Edesa Biotech has a net margin of -339.51% compared to Canopy Growth's net margin of --. Canopy Growth's return on equity of -113.08% beat Edesa Biotech's return on equity of --.

Canopy Growth has a consensus price target of $3.82, signalling upside risk potential of 249.15%. On the other hand Edesa Biotech has an analysts' consensus of $10.33 which suggests that it could grow by 357.23%. Given that Edesa Biotech has higher upside potential than Canopy Growth, analysts believe Edesa Biotech is more attractive than Canopy Growth.

Canopy Growth has a beta of 0.728, which suggesting that the stock is 27.239% less volatile than S&P 500. In comparison Edesa Biotech has a beta of 0.393, suggesting its less volatile than the S&P 500 by 60.718%.

Canopy Growth has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edesa Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Canopy Growth pays -- of its earnings as a dividend. Edesa Biotech pays out -- of its earnings as a dividend.

Canopy Growth quarterly revenues are $45.2M, which are larger than Edesa Biotech quarterly revenues of --. Canopy Growth's net income of -$153.5M is lower than Edesa Biotech's net income of -$1.6M. Notably, Canopy Growth's price-to-earnings ratio is -- while Edesa Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Canopy Growth is 0.61x versus 25.98x for Edesa Biotech. Usually stocks with elevated PS ratios are considered overvalued.

Tilray Brands has a net margin of -339.51% compared to Canopy Growth's net margin of -424.93%. Canopy Growth's return on equity of -113.08% beat Tilray Brands's return on equity of -28.79%.

Canopy Growth has a consensus price target of $3.82, signalling upside risk potential of 249.15%. On the other hand Tilray Brands has an analysts' consensus of $1.22 which suggests that it could grow by 101.59%. Given that Canopy Growth has higher upside potential than Tilray Brands, analysts believe Canopy Growth is more attractive than Tilray Brands.

Canopy Growth has a beta of 0.728, which suggesting that the stock is 27.239% less volatile than S&P 500. In comparison Tilray Brands has a beta of 1.817, suggesting its more volatile than the S&P 500 by 81.7%.

Canopy Growth has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tilray Brands offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Canopy Growth pays -- of its earnings as a dividend. Tilray Brands pays out -- of its earnings as a dividend.

Canopy Growth quarterly revenues are $45.2M, which are smaller than Tilray Brands quarterly revenues of $185.8M. Canopy Growth's net income of -$153.5M is higher than Tilray Brands's net income of -$789.4M. Notably, Canopy Growth's price-to-earnings ratio is -- while Tilray Brands's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Canopy Growth is 0.61x versus 0.63x for Tilray Brands. Usually stocks with elevated PS ratios are considered overvalued.

Treace Medical Concepts has a net margin of -339.51% compared to Canopy Growth's net margin of -30.29%. Canopy Growth's return on equity of -113.08% beat Treace Medical Concepts's return on equity of -47.17%.

Canopy Growth has a consensus price target of $3.82, signalling upside risk potential of 249.15%. On the other hand Treace Medical Concepts has an analysts' consensus of $10.02 which suggests that it could grow by 71.23%. Given that Canopy Growth has higher upside potential than Treace Medical Concepts, analysts believe Canopy Growth is more attractive than Treace Medical Concepts.

Canopy Growth has a beta of 0.728, which suggesting that the stock is 27.239% less volatile than S&P 500. In comparison Treace Medical Concepts has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Canopy Growth has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Treace Medical Concepts offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Canopy Growth pays -- of its earnings as a dividend. Treace Medical Concepts pays out -- of its earnings as a dividend.

Canopy Growth quarterly revenues are $45.2M, which are smaller than Treace Medical Concepts quarterly revenues of $52.6M. Canopy Growth's net income of -$153.5M is lower than Treace Medical Concepts's net income of -$15.9M. Notably, Canopy Growth's price-to-earnings ratio is -- while Treace Medical Concepts's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Canopy Growth is 0.61x versus 1.73x for Treace Medical Concepts. Usually stocks with elevated PS ratios are considered overvalued.

Viatris has a net margin of -339.51% compared to Canopy Growth's net margin of -93.48%. Canopy Growth's return on equity of -113.08% beat Viatris's return on equity of -20.24%.

Canopy Growth has a consensus price target of $3.82, signalling upside risk potential of 249.15%. On the other hand Viatris has an analysts' consensus of $11.3875 which suggests that it could grow by 25.41%. Given that Canopy Growth has higher upside potential than Viatris, analysts believe Canopy Growth is more attractive than Viatris.

Canopy Growth has a beta of 0.728, which suggesting that the stock is 27.239% less volatile than S&P 500. In comparison Viatris has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.435%.

Canopy Growth has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viatris offers a yield of 5.29% to investors and pays a quarterly dividend of $0.12 per share. Canopy Growth pays -- of its earnings as a dividend. Viatris pays out -90.63% of its earnings as a dividend.

Canopy Growth quarterly revenues are $45.2M, which are smaller than Viatris quarterly revenues of $3.3B. Canopy Growth's net income of -$153.5M is higher than Viatris's net income of -$3B. Notably, Canopy Growth's price-to-earnings ratio is -- while Viatris's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Canopy Growth is 0.61x versus 0.76x for Viatris. Usually stocks with elevated PS ratios are considered overvalued.